MONTREAL, Jan. 23 /CNW Telbec/ - Biophage Pharma Inc. (TSX.V: BUG) is
pleased to report that it has concluded the sales of LISTEX(TM) to an
important cheese producer in the US. Securing this sale marks the beginning of
a business relationship with our first client who intends to develop and use
phage therapy as a biological solution to potential Listeria monocytogenes
(Listeria) contamination in cheese.
